Study Summary
This trial looks at whether a drug called Tildrakizumab can help treat psoriasis by reducing the activity of a protein called IL-23.
Eligible Conditions
- Plaque Psoriasis
Treatment Effectiveness
Effectiveness Progress
This is further along than 93% of similar trials
Study Objectives
1 Primary · 0 Secondary · Reporting Duration: baseline and 3 months
baseline and 3 months
Change in Psoriasis Area and Severity Index (PASI) Score from Baseline to 3 months
Trial Safety
Safety Progress
This is further along than 85% of similar trials
Trial Design
1 Treatment Group
Tildrakizumab treatment
1 of 1
Experimental Treatment
40 Total Participants · 1 Treatment Group
Primary Treatment: Tildrakizumab · No Placebo Group · Phase 4
Tildrakizumab treatment
Biological
Experimental Group · 1 Intervention: Tildrakizumab · Intervention Types: BiologicalTreatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Tildrakizumab
FDA approved
Trial Logistics
Trial Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: baseline and 3 months
Who is running the clinical trial?
University of California, San FranciscoLead Sponsor
2,283 Previous Clinical Trials
11,577,734 Total Patients Enrolled
Sun Pharmaceutical Industries LimitedIndustry Sponsor
59 Previous Clinical Trials
13,463 Total Patients Enrolled
Raymond Cho, MD, PhDPrincipal InvestigatorUniversity of California, San Francisco
1 Previous Clinical Trials
10 Total Patients Enrolled
Eligibility Criteria
Age 18+ · All Participants · 3 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:You have psoriasis or atypical psoriasis.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Conditions
Cancer Related
Treatments